Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Albireo Pharma Inc (NASDAQ:ALBO)

26.99
Delayed Data
As of 3:59pm ET
 +0.39 / +1.47%
Today’s Change
14.00
Today|||52-Week Range
37.69
+52.23%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$236.3M

Company Description

Albireo Pharma, Inc. is a pharmaceutical company engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions. Its product pipeline includes A4250, developed for children with chronic cholestasis; and A3384 designed to deliver cholestyramine directly to the colon. The company was founded by Jan Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Contact Information

Albireo Pharma, Inc.
10 Post Office Square
Boston Massachusetts 02109
P:(857) 254-5555
Investor Relations:

Employees

Shareholders

Mutual fund holders3.47%
Other institutional15.69%
Individual stakeholders1.39%

Top Executives

Ron CooperPresident, Chief Executive Officer & Director
Jan Peter MattssonChief Operating Officer
Mike GutchCFO, Director & Chief Business Officer
Paresh N. SoniChief Medical & Scientific Officer
Alan Seth KrasnerChief Medical Officer